Company news

Karyopharm Therapeutics Inc. news in 2021

Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.

View company

Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories

December 20, 2021

Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition

December 10, 2021

Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors

December 5, 2021

Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis

December 5, 2021

Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer

December 1, 2021

Karyopharm to Host Virtual Investor Day on December 8, 2021

November 30, 2021

Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

November 3, 2021

Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights

November 2, 2021

Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome

October 20, 2021

Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results

August 4, 2021

Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021

July 28, 2021

Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

July 27, 2021

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

June 23, 2021

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

June 8, 2021

Karyopharm Announces Key Changes to Its Commercial Leadership Team

June 7, 2021

Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets

June 2, 2021

Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

June 1, 2021

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

May 18, 2021

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

May 2, 2021

Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021

April 27, 2021

Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology

April 18, 2021

Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

March 28, 2021

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress

February 10, 2021

Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma

February 3, 2021

Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

January 28, 2021

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update

January 10, 2021

Calls in 2021

Decks in 2021